BRN2 is a non-canonical melanoma tumor-suppressor

8Citations
Citations of this article
32Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

While the major drivers of melanoma initiation, including activation of NRAS/BRAF and loss of PTEN or CDKN2A, have been identified, the role of key transcription factors that impose altered transcriptional states in response to deregulated signaling is not well understood. The POU domain transcription factor BRN2 is a key regulator of melanoma invasion, yet its role in melanoma initiation remains unknown. Here, in a BrafV600EPtenF/+ context, we show that BRN2 haplo-insufficiency promotes melanoma initiation and metastasis. However, metastatic colonization is less efficient in the absence of Brn2. Mechanistically, BRN2 directly induces PTEN expression and in consequence represses PI3K signaling. Moreover, MITF, a BRN2 target, represses PTEN transcription. Collectively, our results suggest that on a PTEN heterozygous background somatic deletion of one BRN2 allele and temporal regulation of the other allele elicits melanoma initiation and progression.

Cite

CITATION STYLE

APA

Hamm, M., Sohier, P., Petit, V., Raymond, J. H., Delmas, V., Le Coz, M., … Larue, L. (2021). BRN2 is a non-canonical melanoma tumor-suppressor. Nature Communications, 12(1). https://doi.org/10.1038/s41467-021-23973-5

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free